PlasmaTech Biopharmaceuticals Announces Closing of Upsized

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PlasmaTech Biopharmaceuticals Announces Closing of Upsized $7 Million Private Placement

DALLAS, TX and NEW YORK, NY --(Marketwired - April 24, 2015) - PlasmaTech Biopharmaceuticals, Inc. ( NASDAQ : PTBI ), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had closed an upsized $7 million private placement of common stock with Knoll Capital Management and one additional global institutional fund manager. The private financing is comprised of 2,333,333 shares of common stock at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF™) Plasma Protein technology, working capital and general corporate purposes.

"We are pleased and excited to have both a new high quality institutional investor, and with the expanded participation of a current investor, to enable the build out of our proprietary plasma protein extraction and purification process," stated Steve H. Rouhandeh, PlasmaTech's Executive Chairman. "We look forward to a constructive and dynamic relationship moving forward."

The securities sold in this financing have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Plasma Proteins and the SDF™ Process: The global market for drugs derived from human blood plasma fractionation is currently greater than US$15 billion, and is growing at a rate close to 10% annually. Despite this significant market opportunity, limited innovation in fractionation technology has occurred in decades. PTBI has developed and patented a new extraction process for plasma biologics that may fundamentally change the economics of blood plasma fractionation, and makes possible the extraction of several additional therapeutically useful plasma proteins. The Company believes that PlasmaTech's proprietary fractionation process is expected to significantly enhance yields of specific high-value proteins, including alpha-1 antitrypsin, expanding market opportunities while greatly enhancing margins. The Company believes that PlasmaTech's lead product opportunity, alpha-1 antitrypsin ("AAT"), will offer a potentially high revenue, short time-to-market respiratory product for treatment of inherited COPD, or alpha-1 antitrypsin deficiency ("AATD"), among other indications. In addition, the SDF process is expected to produce higher yields of other high-value proteins with significant therapeutic benefit.

About PlasmaTech: PlasmaTech is a biopharmaceutical company focused on advancing protein biologic therapies and oncology supportive care products. Exploiting two proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, with additional follow-on products in development. For more information, visit www.plasmatechbio.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, those relating to: the private placement described in this press release, our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and ProctiGard, the global market for drugs derived from human blood plasma and its growth rate, expectations relating to AAT, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contact: Andre'a Lucca Director of Communications PlasmaTech Biopharmaceuticals, Inc. 212-786-6208 alucca@plasmatechbio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 100

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 67

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 162

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 207

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 65

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 94

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 173

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 90

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the New Beach Bungalows at Margaritaville Resort

Updated Category News Views 98

Unveiling the Beach Bungalows at Margaritaville Resort Camp Margaritaville Resort Crystal Beach is thrilled to unveil its brand-new residential offering, the Beach Bungalows. This exciting development invites potential homeowners to experience life along the enchanting shores of Crystal Beach. Experience Coastal Living Like Never Before For those seeking a tranquil...

Continue Reading
Carrier Global Corporation Declares New Quarterly Dividend

Updated Category News Views 199

Carrier Global Corporation Announces Quarterly Cash Dividend Carrier Global Corporation (NYSE: CARR), a leading entity in intelligent climate and energy solutions, is excited to inform its stakeholders about the declaration of a quarterly cash dividend. This dividend amounts to $0.225 for each share of the common stock held by shareholders. Dividend Payment and Record...

Continue Reading
Investors Alert: Class Action Filed Against Synopsys, Inc.

Updated Category News Views 127

Understanding the Class Action Lawsuit Against Synopsys, Inc. Recently, a class action lawsuit has been initiated against Synopsys, Inc. (NASDAQ: SNPS), centered around claims of securities fraud. This move, announced by Bernstein Liebhard LLP, has raised significant attention among shareholders who purchased or acquired securities of the Company. Who Should Be Concerned?...

Continue Reading
Modern Pediatrics Introduces Affordable Care with Home Visits

Updated Category News Views 319

Modern Pediatrics Launches Affordable Pediatric Care in Dallas Modern Pediatrics, a concierge pediatrics group based in Austin, is excited to bring their innovative services to the Dallas area. They are now offering in-home pediatric visits and 24/7 virtual care, a service that is truly a game-changer for families seeking accessible healthcare. Historically, home-based...

Continue Reading
Texas Pacific Land Corp Reports Insider Stock Purchases

Updated Category News Views 95

Executives at Texas Pacific Land Corp Make Noteworthy Stock Purchases Recently, executives at Texas Pacific Land Corp (NYSE: TPL), a key player in the oil royalty trading sector, made significant stock purchases. These transactions, revealed through recent SEC filings, were conducted under a prearranged trading plan, which allows insiders to buy shares without raising...

Continue Reading